Mibefradil

Mibefradil
Systematic (IUPAC) name
(1S,2S)-2-(2-((3-(1H-benzo[d]imidazol-2-yl)propyl) (methyl)amino)ethyl)-6-fluoro-1-isopropyl- 1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
MedlinePlus a607007
Routes of
administration
Oral
Legal status
  • Withdrawn from market
Pharmacokinetic data
Bioavailability 70 %
Protein binding > 99 %
Metabolism Hepatic
Biological half-life 17-25 h
Identifiers
CAS Number 116644-53-2 YesY
ATC code C08CX01 (WHO)
PubChem CID 60662
IUPHAR/BPS 2522
DrugBank DB01388 N
ChemSpider 54673 N
UNII 27B90X776A N
KEGG D08217 YesY
ChEMBL CHEMBL45816 N
Chemical data
Formula C29H38FN3O3
Molar mass 495.63 g/mol
Physical data
Melting point 128 °C (262 °F) (dihydrochloride salt)
 NYesY (what is this?)  (verify)

Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers.

The mechanism of action of mibefradil is characterized by the selective blockade of transient, low-voltage-activated (T-type) calcium channels over long-lasting, high-voltage-activated (L-type) calcium channels, which is probably responsible for many of its unique properties.

It is nonselective.[1]

On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications. [2]

Synthesis

Mibefradil synthesis: YU 22988  ZW 20087 

References


This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.